Drug Approval | January 21, 2022
Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Ram’s appointment follows the launch of the CDI India division in October 2021.
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
They will commercialize molnupiravir in the international markets
The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
Krivida Novus can detect the Omicron variant and its sub-lineages in 45 minutes
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
_256_384.jpg)
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
Subscribe To Our Newsletter & Stay Updated
